SCHEMBL764570

SCHEMBL764570

CCOC(=O)N1CCC(Nc2ccc(C)cc2)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.65
KDM4E B2RXH2 2/20 0.62
LMNA P02545 1/20 0.62
NOS2 P35228 4/20 0.62
NOS1 P29475 3/20 0.62
NOS3 P29474 1/20 0.62
MAPT P10636 4/20 0.60
GAA P10253 2/20 0.60
USP2 O75604 1/20 0.59
ABL1 P00519 1/20 0.58
POLB P06746 1/20 0.58
RIN1 Q13671 1/20 0.58
TDP1 Q9NUW8 1/20 0.58
NPSR1 Q6W5P4 1/20 0.57
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16359223 0.90 KDM4E (0.61) ALDH1A1KDM4ELMNANOS2NOS1
SCHEMBL11457429 0.89 KDM4E (0.63) ALDH1A1KDM4ELMNANOS2NOS1
SCHEMBL1196914 0.86 NOS2 (0.65) ALDH1A1KDM4ELMNANOS2NOS1
SCHEMBL22634120 0.84 KDM4E (0.64) ALDH1A1KDM4ELMNANOS2NOS1
SCHEMBL4115820 0.83 ALDH1A1 (0.77) ALDH1A1LMNAMAPTABL1RIN1
SCHEMBL596620 0.82 MAPT (0.54) ALDH1A1KDM4ELMNANOS2NOS1
SCHEMBL596621 0.82 MAPT (0.54) ALDH1A1KDM4ELMNANOS2NOS1
SCHEMBL13813506 0.82 ALDH1A1 (0.51) ALDH1A1KDM4ELMNANOS2NOS1
SCHEMBL4693278 0.82 MAPT (0.51) ALDH1A1KDM4ELMNAMAPTPOLB
SCHEMBL10371811 0.81 ALDH1A1 (0.58) ALDH1A1KDM4ELMNANOS2NOS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8372860-B2 Carboline derivatives useful in the inhibition of angiogenesis PTC THERAPEUTICS, INC. (US) 2013-02-12 US disclosed
US-20100179132-A1 CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS PTC THERAPEUTICS, INC. 2010-07-15 US disclosed
US-20100158858-A1 ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES PTC THERAPEUTICS, INC. 2010-06-24 US disclosed
US-7601840-B2 Carboline derivatives useful in the inhibition of angiogenesis PTC THERAPEUTICS, INC. (US) 2009-10-13 US disclosed
US-20070281962-A2 Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration PCT THERAPEUTICS, INC. (US) 2007-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100158858-A1 ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES RNMT, VEGFA, VHL ALDH1A1 1851/4885KDM4E 978/4885LMNA 3138/4885
US-20070281962-A2 Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration VEGFA, FLT4, MIF ALDH1A1 1537/4885KDM4E 797/4885LMNA 3199/4885
US-20100179132-A1 CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS VEGFA, FLT4, PGF ALDH1A1 1035/4885KDM4E 407/4885LMNA 4374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.